Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT04050800
Other study ID # 19-05020069
Secondary ID
Status Completed
Phase Early Phase 1
First received
Last updated
Start date September 17, 2020
Est. completion date January 5, 2021

Study information

Verified date June 2021
Source Weill Medical College of Cornell University
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This will be a Phase 1, open label, imaging study of radiochemical and radiation safety in healthy volunteers. Using positron emission tomography (PET) and in-line computed tomography (CT), the whole body (WB) biokinetics of Carbon-11 butanol will be quantified with serial scans acquired every 3 minutes for two hours. Vital signs (VS), electrocardiograms (ECGs) and clinical laboratory tests of intrernal organ function will be acquired before and at several timepoints after administration of the radiopharmaceutical. Radiation exposures will be estimated with the MIRD Formalism.


Description:

Vital signs (VSs) will be measured, electrocardiograms (ECGs) will be acquired, and blood will be sent to the clinical laboratory for safety assessments before a single dose, intravenous (IV) administration of 555 MBq of Carbon-11 butanol. VSs will be re-measured, ECGs will be acquired again, and more blood will be sent to the clinical laboratory for repeat safety assessments after 2 hours of whole body (WB) scanning. WB scanning will consist of imaging acquisition sweeps of 200 cm from head-to-toe over 180 secs (3 min). Up to 40 sweeps per imaging session will be performed. The subjects will then be given a rest period ("coffee break") for about two hours, after which the entire sequence of events will be repeated. The primary outcome measure will be related to radiation safety derived from the areas under the time-activity curves (AUCs) for internal organs. Co-primary clinical safety measures will include changes in VSs, ECG parameters such as the PR and corrected QT intervals, and clinical laboratory tests, such as proteins that reflect renal and hepatic function. Secondary endpoints will include the time-activity curves (TACs) and total volumes of distribution (VT) in several brain regions. The results should allow calculation of the repeatability coefficients (RCs) under zero-biological-change conditions. RC values will be essential for understanding whether future measurements of effect sizes in response to therapeutic maneuvers or the differences between groups are meaningful.


Recruitment information / eligibility

Status Completed
Enrollment 5
Est. completion date January 5, 2021
Est. primary completion date December 29, 2020
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 18 Years to 89 Years
Eligibility Inclusion Criteria: - able to give informed consent. - age 18-89 - Subjectively healthy and, in the opinion of the investigators, likely to tolerate the imaging procedures and be compliant with the schedule of follow up telephone calls. - Normal hemodynamic function. Systolic blood pressure and pulse must be higher than 120 mmHg and 60 beats per minute while sitting. At the discretion of the investigators, people who regularly engage in vigorous exercise more than four times per week may be enrolled if their systolic blood pressure and pulse are higher than 100 mmHg and 50 beats per minute while sitting. - Unremarkable electrocardiograms, with PR intervals of less than 200 mSec and QTcF intervals (corrected with Frederica's method) of less than 440 mSec. - No concurrent medications with the exception of p.r.n. NSAIDS, which must be discontinued one week prior to PET scanning. - Willing and able to refrain from abusing any recreational drugs, including marijuana, and drink less than one unit of alcoholic beverages per day starting one week prior to PET scanning, and avoided for the next four weeks. - Willing to refrain from donating blood for four (4) weeks before the study and for four (4) weeks after the study. - Willing to refrain from participating in any other research study that requires taking medication for four (4) weeks before the study and for four (4) weeks after the study. - Willing to refrain from being vaccinated for four (4) weeks before the study and for four (4) weeks after the study. - All clinical laboratory test results within normal limits or not clinically significant. For example, elevated bilirubin levels in subjects with Gilbert's syndrome will be allowed, as will small red blood cell volumes in healthy people with sickle cell trait. Exclusion Criteria: - Subjects may not be a member of a vulnerable population. - Women may not be pregnant or breast feeding. - History of multiple hypersensitivity reactions (atopia), as indicated by allergies to multiple medications, foods, and seasonal pollens. - History, physical examination, or clinical laboratory tests suggestive of a condition, disorder, or disease that could adversely affect drug absorption, distribution, metabolism, or elimination (ADME) of the tracer, including chronic liver or renal failure. - Positive urine toxicology screen for recreational drugs other than marijuana. - May not have taken any controlled medications, including other study drugs, in the 30 days prior to PET scanning or for 10 half-lives, whichever is longer. - May not have donated blood in the 30 days prior to PET scanning. - May not have participated in research administering drugs in the last 30 days. - May not have been vaccinated in the 30 days prior to PET scanning. - May not have been exposed to radiation during research of more than 10 mSv during the last year.

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Carbon 11 Butanol
Two sequential administrations of a PET tracer

Locations

Country Name City State
United States Weill Cornell Medicine New York New York

Sponsors (1)

Lead Sponsor Collaborator
Weill Medical College of Cornell University

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Effective Dose (ED) Fundamental radiation dose quantity in the International Commission on Radiological Protection (ICRP) system of radiological protection. Calculated with OLINDA-EXM software (OLINDA/EXM stands for Organ Level INternal Dose Assessment/EXponential Modeling). Day 1, from the measurements of exposures during the first 2 hours post administration.
Secondary Change in Radiochemical Safety Assessments Change in pulse Pulse at two hours post administration compared to pulse shortly before administration.
Secondary Change in Radiochemical Safety Assessments Change in blood pressure Blood pressure at two hours post administration compared to blood pressure shortly before administration.
Secondary Change in Radiochemical Safety Assessments Change in heart rhythm on electrocardiogram (ECG) At two hours post administration compared to same parameters shortly before administration.
Secondary Change in number of Subjects with prolonged PR interval greater than 20 mSec Change in PR interval on electrocardiogram (ECG) At two hours post administration compared to same parameters shortly before administration.
Secondary Change in number of subjects with QTc >440 mSec Change in corrected QT interval on electrocardiogram (ECG). At two hours post administration compared to same parameters shortly before administration.
See also
  Status Clinical Trial Phase
Active, not recruiting NCT05586750 - Statins in Reducing Events in the Elderly Mind (STAREE-Mind) Imaging Substudy Phase 4
Recruiting NCT04863859 - Persons With Dementia and Their Extended Family Caregivers
Recruiting NCT05655650 - Identifying Biomarkers in Alzheimer's Disease
Completed NCT04937127 - Efficiency of E-learning and Role-playing for the Training of Nursing Home Caregivers in the Support of Agitation in Neurodegenerative Diseases
Enrolling by invitation NCT03197363 - BiaƂystok PLUS - Polish Longitudinal University Study
Enrolling by invitation NCT03322306 - Establishment of Genetic Basis for Neurological Disease by Genetic Screening
Completed NCT03439163 - Large Sample PD Patients and Healthy Controls N/A
Withdrawn NCT05921929 - First-In-Human (FIH), Single Ascending Dose (SAD) Study of FluoroEthylNorMemantine (FENM) Phase 1
Recruiting NCT05209698 - Self-Management Behaviors of Arabs and Jews With Parkinson's Disease and Their Associations With Health Outcomes
Completed NCT04362228 - The Effects of Whole-body Exercise to Improve Swallowing Function in Older Adults With Dementia N/A
Enrolling by invitation NCT05008094 - The Epidemiology of Parkinson's Disease in Croatia and the Influence of Genetic Factors and Microbiota on the Progression and Treatment Outcomes of the Disease (GiOPARK)
Completed NCT03279991 - Neuromed- Integrated Health Life Platform and Biobank
Active, not recruiting NCT04228653 - Long-Term Follow-up Safety After DDS Implantation With/Without CDNF Infusions Phase 1/Phase 2
Recruiting NCT05328492 - Volume Mode Non-invasive Ventilation in Amyotrophic Lateral Sclerosis N/A
Not yet recruiting NCT06151600 - A Prospective Natural History and Outcome Measure Discovery Study of Charcot-Marie-Tooth Disease, Type 4J
Recruiting NCT04880356 - Longitudinal Study of Ultra-rare Inherited Metabolic and Degenerative Neurological Diseases.
Active, not recruiting NCT03609125 - Cord Blood Serum in the Treatment of Neuro-Degenerative Ophthalmic Diseases. 1-Glaucoma N/A
Recruiting NCT03153670 - 3T MRI in Patients With Deep Brain Stimulation (DBS) N/A
Completed NCT03775538 - Safety of CDNF by Brain Infusion in Patients With Parkinson's Disease. Extension to HP-CD-CL-2002 Clinical Study Phase 1/Phase 2
Enrolling by invitation NCT04635540 - Decreased Empathy and Emotion Recognition in Patients With Neurodegenerative Disease N/A